Search

Corvus Pharmaceuticals Inc

Ouvert

14.23 1.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.81

Max

14.16

Chiffres clés

By Trading Economics

Revenu

-4.3M

-18M

BPA

-0.19

Employés

37

EBITDA

-5.3M

-17M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+110.11% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

61M

1.2B

Ouverture précédente

12.95

Clôture précédente

14.23

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 août 2026, 23:56 UTC

News

Array Technologies has acquired Affordable Wire Management, enhancing its portfolio and growth potential. Shares are trading slightly higher in after-market hours.

31 août 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

31 août 2026, 23:56 UTC

Correlated Moves

Regal Rexnord Corp shares are higher in after-market trading, reflecting a cumulative return of 0.44% since Monday's close amid similar trends from Eaton Corporation PLC.

31 août 2026, 23:56 UTC

Schrodinger Inc shares are higher in after-hours trading, influenced by rising oil prices and inflation concerns ahead of the Federal Reserve meeting.

31 août 2026, 23:56 UTC

Mosaic Co's shares are lower in after-market hours, reflecting inflation concerns from rising oil prices ahead of the Federal Reserve meeting.

31 août 2026, 23:56 UTC

TransDigm Group Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid overall weak market performance.

31 août 2026, 23:56 UTC

News

Frontier Group Holdings plans to terminate leases for 13 A320neo aircraft, leading to anticipated charges of $60 million to $80 million. Shares are lower in after-market hours.

31 août 2026, 23:56 UTC

Exelon Corp shares are lower in after-market trading, following fluctuations since Monday's close. Rising oil prices and inflation concerns influence broader market sentiment.

31 août 2026, 23:56 UTC

Shell PLC shares are lower in after-market trading, following a slight decline since Monday's close. Oil prices have risen, impacting broader market sentiment.

31 août 2026, 23:56 UTC

abrdn Physical Palladium Shares ETF traded roughly flat after-market hours, with no specific news identified. Global equity indices are mixed amid inflation concerns.

31 août 2026, 23:52 UTC

Japan's Q2 2026 Capital Spending YoY forecasted to rise only 0.2%, signaling subdued private investment growth amid cautious market sentiment.

31 août 2026, 23:52 UTC

South Korea's S&P Global Manufacturing PMI release on September 1 faces cautious market sentiment amid rising oil prices and inflation concerns.

31 août 2026, 23:52 UTC

Federal Reserve Chair Kevin Warsh's hawkish remarks boost interest rate hike expectations to 60-65% amid rising inflation concerns and geopolitical tensions.

31 août 2026, 23:52 UTC

ISM Manufacturing Employment Data Release on September 1, 2026, Sparks Caution Amid Inflation Concerns and Fed Rate Hike Speculation.

31 août 2026, 23:52 UTC

ISM Manufacturing PMI Release on September 1 Expected to Show Continued Growth Amid Geopolitical Tensions and Fed Rate Hike Speculation.

31 août 2026, 23:52 UTC

Australia's Balance of Trade data set for September 3, 2026, anticipates a AUD 1.4 billion surplus amid mixed market sentiment and geopolitical tensions affecting investor confidence.

31 août 2026, 23:52 UTC

JOLTs Job Openings Report on September 1 Expected to Influence Fed Rate Hike Decisions Amid Geopolitical Tensions and Inflation Concerns.

31 août 2026, 23:52 UTC

U.S. Initial Jobless Claims Expected at 205K Amid Inflation Concerns and Fed Rate Hike Speculation

31 août 2026, 23:52 UTC

Japan's Q2 2026 GDP Growth Rate Expected at 0.3%, Sparking Speculation of Interest Rate Hike Amid Mixed Economic Sentiment

31 août 2026, 23:52 UTC

Japan's Q2 2026 GDP Growth Release Expected at 1.1% Amid Mixed Economic Signals and Potential BoJ Interest Rate Hikes

31 août 2026, 23:51 UTC

Enterprise Financial Services Corp shares are lower in after-market trading, lacking any specific news to explain the decline. The stock remains below its 20-day moving average.

31 août 2026, 23:51 UTC

Dyadic International Inc shares are higher in after-market hours, showing strong buying interest despite a recent significant decline and downward pressure over the past sessions.

31 août 2026, 23:51 UTC

Wayfair Inc shares are lower in after-market trading, reversing a trend of higher daily closes. No specific news was identified to explain the decline.

31 août 2026, 23:51 UTC

United Parks & Resorts Inc. shares are higher in after-market trading, reflecting notable strength despite no specific company news identified.

31 août 2026, 23:51 UTC

Playtika Holding Corp shares are higher in after-market trading. No specific news was identified to explain this movement amid broader market volatility.

31 août 2026, 23:51 UTC

European equity markets decline amid rising oil prices and inflation concerns following U.S.-Iran military tensions, with investors cautious ahead of key economic data.

31 août 2026, 23:51 UTC

U.S. equity indices decline amid rising oil prices and geopolitical tensions, with Fed rate hike expectations intensifying.

31 août 2026, 23:51 UTC

Asia equity markets mixed as Middle East tensions and hawkish Fed signals drive oil prices up and investor caution.

31 août 2026, 23:51 UTC

U.S. and European markets decline amid rising oil prices and inflation fears following U.S.-Iran tensions, while Dallas Fed Manufacturing Index signals strong recovery.

31 août 2026, 23:51 UTC

Helmerich and Payne Inc. shares are higher in after-market trading, supported by a rise in Brent crude futures amid geopolitical tensions in the Strait of Hormuz.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

110.11% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD  110.11%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat